Beijing LiangYuan Bioscience

Beijing Liangyuan Bioscience is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company's primary focus is on targeting deubiquitinating enzymes (DUBs), a protein family that plays a critical role in protein degradation and DNA damage repair. Its lead program, LY001, is a potent and selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1), currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Liangyuan Bioscience leverages its proprietary DUB-targeting platform to develop precision medicines that address resistance mechanisms in cancer, such as those encountered with PARP inhibitors. The company is backed by prominent investors including IDG Capital and 5Y Capital, supporting its mission to deliver first-in-class treatments to patients globally.